Literature DB >> 19636546

The development of an objective methodology to measure medication adherence to oral thiopurines in paediatric patients with acute lymphoblastic leukaemia--an exploratory study.

Ahmed F Hawwa1, Jeff S Millership, Paul S Collier, Anthony McCarthy, Sid Dempsey, Carole Cairns, James C McElnay.   

Abstract

AIMS: To develop a method that prospectively assesses adherence rates in paediatric patients with acute lymphoblastic leukaemia (ALL) who are receiving the oral thiopurine treatment 6-mercaptopurine (6-MP).
METHODS: A total of 19 paediatric patients with ALL who were receiving 6-MP therapy were enrolled in this study. A new objective tool (hierarchical cluster analysis of drug metabolite concentrations) was explored as a novel approach to assess non-adherence to oral thiopurines, in combination with other objective measures (the pattern of variability in 6-thioguanine nucleotide erythrocyte concentrations and 6-thiouric acid plasma levels) and the subjective measure of self-reported adherence questionnaire.
RESULTS: Parents of five ALL patients (26.3%) reported at least one aspect of non-adherence, with the majority (80%) citing "carelessness at times about taking medication" as the primary reason for non-adherence followed by "forgetting to take the medication" (60%). Of these patients, three (15.8%) were considered non-adherent to medication according to the self-reported adherence questionnaire (scored > or = 2). Four ALL patients (21.1%) had metabolite profiles indicative of non-adherence (persistently low levels of metabolites and/or metabolite levels clustered variably with time). Out of these four patients, two (50%) admitted non-adherence to therapy. Overall, when both methods were combined, five patients (26.3%) were considered non-adherent to medication, with higher age representing a risk factor for non-adherence (P < 0.05).
CONCLUSIONS: The present study explored various ways to assess adherence rates to thiopurine medication in ALL patients and highlighted the importance of combining both objective and subjective measures as a better way to assess adherence to oral thiopurines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636546     DOI: 10.1007/s00228-009-0700-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  How low is too low? Use of cluster analysis to define low levels of mercaptopurine metabolites.

Authors:  Fatoumata Traore; Mary Ann O'Riordan; Carolyn Myers; Karen Groth; Ahna Hoff; Anne Angiolillo; Susan Rheingold; Dennis Drotar; Eric Kodish
Journal:  Pediatr Blood Cancer       Date:  2006-02       Impact factor: 3.167

Review 2.  Compliance with oral chemotherapy in childhood lymphoblastic leukaemia.

Authors:  H A Davies; J S Lilleyman
Journal:  Cancer Treat Rev       Date:  1995-03       Impact factor: 12.111

Review 3.  Adherence to therapy with oral antineoplastic agents.

Authors:  Ann H Partridge; Jerry Avorn; Philip S Wang; Eric P Winer
Journal:  J Natl Cancer Inst       Date:  2002-05-01       Impact factor: 13.506

4.  Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia.

Authors:  R C Lau; D Matsui; M Greenberg; G Koren
Journal:  Med Pediatr Oncol       Date:  1998-02

5.  Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.

Authors:  Karin Dilger; Elke Schaeffeler; Milan Lukas; Ulrike Strauch; Hans Herfarth; Ralph Müller; Matthias Schwab
Journal:  Ther Drug Monit       Date:  2007-02       Impact factor: 3.681

6.  Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.

Authors:  Ahmed F Hawwa; Jeff S Millership; Paul S Collier; Koen Vandenbroeck; Anthony McCarthy; Sid Dempsey; Carole Cairns; John Collins; Colin Rodgers; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

7.  Psychological correlates of compliance.

Authors:  S B Lansky; S D Smith; N U Cairns; G F Cairns
Journal:  Am J Pediatr Hematol Oncol       Date:  1983

8.  Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.

Authors:  Ahmed F Hawwa; Paul S Collier; Jeff S Millership; Anthony McCarthy; Sid Dempsey; Carole Cairns; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

9.  Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment.

Authors:  R S Festa; M H Tamaroff; F Chasalow; P Lanzkowsky
Journal:  J Pediatr       Date:  1992-05       Impact factor: 4.406

10.  Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?

Authors:  L Lennard; J Welch; J S Lilleyman
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more
  11 in total

1.  Medical and psychosocial associates of nonadherence in adolescents with cancer.

Authors:  Stephanie E Hullmann; Lauren D Brumley; Lisa A Schwartz
Journal:  J Pediatr Oncol Nurs       Date:  2014-11-03       Impact factor: 1.636

2.  The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.

Authors:  Dawn L Hershman; Jennifer Tsui; Jay Meyer; Sherry Glied; Grace Clarke Hillyer; Jason D Wright; Alfred I Neugut
Journal:  J Natl Cancer Inst       Date:  2014-10-27       Impact factor: 13.506

3.  Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer.

Authors:  Alfred I Neugut; Milayna Subar; Elizabeth Ty Wilde; Scott Stratton; Corey H Brouse; Grace Clarke Hillyer; Victor R Grann; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

4.  Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.

Authors:  Dawn L Hershman; Jennifer Tsui; Jason D Wright; Ellie J Coromilas; Wei Yann Tsai; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2015-02-17       Impact factor: 44.544

5.  Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003.

Authors:  Lynne Lennard; Cher S Cartwright; Rachel Wade; Ajay Vora
Journal:  Br J Haematol       Date:  2015-05-05       Impact factor: 6.998

6.  Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia.

Authors:  Mervat Alsous; Rana Abu Farha; Eman Alefishat; Suha Al Omar; Deema Momani; Alia Gharabli; James McElnay; Robert Horne; Rawad Rihani
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

7.  Unusual causes of papilledema: Two illustrative cases.

Authors:  Ha Son Nguyen; Kathryn M Haider; Laurie L Ackerman
Journal:  Surg Neurol Int       Date:  2013-04-18

8.  Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study.

Authors:  Ahmed F Hawwa; AbdelQader AlBawab; Madeleine Rooney; Lucy R Wedderburn; Michael W Beresford; James C McElnay
Journal:  Arthritis Res Ther       Date:  2015-10-22       Impact factor: 5.156

9.  Adolescents and young adults with cancer: aspects of adherence - a questionnaire study.

Authors:  Anne Marie Kleinke; Carl Friedrich Classen
Journal:  Adolesc Health Med Ther       Date:  2018-05-01

10.  When Multiple Objective Measures of Medication Adherence Indicate Incongruent Adherence Results: An Example with Pediatric Cancer.

Authors:  Caitlin J Cain; Andrea R Meisman; Kirstin Drucker; Evrosina I Isaac; Tanvi Verma; Jordyn Griffin; Jennifer M Rohan
Journal:  Int J Environ Res Public Health       Date:  2020-03-17       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.